---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-229184"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T00:54:48.107445+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology enters $100M note purchase agreement to refinance prior credit facility

## Summary
- Issued $100M notes to Athyrium; $25M additional available; used proceeds plus ~$9.2M to repay prior $100M facility.
- Notes bear 8.0% + 3-month LIBOR; quarterly interest; principal amortization starts June 2024, maturity July 2026.
- Covenants require minimum cash and minimum NERLYNX-based revenue; secured by substantially all assets including IP.
- Prepayment fees: make-whole within 2 years, 2% thereafter to year 3; exit fee 2% on any prepayment.
- Restrictions on additional debt, dividends, mergers, asset sales, and change of control.

## SEC filing metadata
- accession: 0001193125-21-229184
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000119312521229184/0001193125-21-229184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000119312521229184/d155853d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-229184
- JSON: https://secwatch.observer/filing/0001193125-21-229184.json
- Plain text: https://secwatch.observer/filing/0001193125-21-229184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.